Table 1 Demographic, baseline clinical, and medications among the two groups
| Â | Carvedilol group (N = 25) | Nebivolol group (N = 18) | P value |
|---|---|---|---|
Age | 50.5 ± 10.5 | 50.9 ± 9.6 | 0.89 |
Wt (kg ) | 83.3 ± 12 | 81.4 ± 10 | 0.58 |
BMI(kg/m2) | 37.0 ± 6.1 | 36.8 ± 4.3 | 0.9 |
Waist circum(cm ) | 118.6 ± 10.5 | 117.3 ± 9.9 | 0.68 |
Male gender | 14 (56%) | 10 (55.6%) | o.8 |
Smokers | 8 (33%) | 4 (22.2%) | 0.48 |
TG (mg/dl) | 132 ± 4.5 | 134 ± 3.5 | 0.12 |
HDL(mg/dl) | 38 ± 6.2 | 39 ± 5.3 | 0.59 |
Uric acid(mg/dl) | 8.1 ± 2.6 | 8.0 ± 2.3 | 0.89 |
Hb% (gm) | 13.5 ± 1.2 | 13.0 ± 2.1 | 0.36 |
Medications | Â | Â | Â |
 Loop diuretic | 17 (68%) | 12 (66.7%) | 0.93 |
 Aldosterone blocker | 15 (60%) | 5 (27.8%) | 0.036* |
 RAS blocker | 23 (92%) | 17 (94.4%) | 0.99 |
 Digoxin | 6 (24%) | 4 (22.2%) | 0.99 |
 ASA | 19 (76%) | 14 (77.8%) | 0.99 |